Pfizer betting big on Asia

News Flash

For full coverage of Budget 2009, log on to Budget.ndtv.com
CUTS BPLR BY 25 BPS TO 12% WITH EFFECT FROM JULY 25
SMS BOS < space > stock query at 56388
EUROPEAN MKTS DROP FOR 3RD STRAIGHT WEEK; DAX DN 1.4% FOR THE WEEK
EUROPEAN STOCKS DROP FOR 3RD STRAIGHT WEEK; DAX DN 1.4% THIS WEEK
RNRL ASKS SUPREME COURT TO DIRECT RIL TO IMPLEMENT BOMBAY HC ORDER
RNRL FILES PETITION IN SC SEEKING MODIFICATIONS TO BOMBAY HC ORDER
RIL MOVES SUPREME COURT CHALLENGING BOMBAY HIGH COURT JUDGEMENT
RIL ALLEGES THAT BOMBAY HC ERRED IN DECIDING QUANTITY, TENURE, PRICE OF GAS
ALL ABOUT ADS, CANNES SPECIAL ON NDTV PROFIT ON SUNDAY 1.30PM
Surprise your loved ones with flowers.log onto NDTVgifts.com
Free shipping in 500 cities. Log onto NDTVgifts.com
For midnight delivery of gifts log onto NDTVgifts.com
For budget news, SMS BUD to 56388
Email us at buyorsell@ndtv.com
Call us at 011-26201171
BUDGET BUILD UP- INDIA'S TOP MINISTERS: AT 1 PM & 10:30 PM, SUN 3 PM
BUDGET BUILD UP- INDIA'S TOP MINISTERS: AT 1 PM & 10:30 PM, SUN 3 PM
BUDGET BUILD UP- INDIA'S TOP MINISTERS: AT 1 PM & 10:30 PM, SUN 3 PM
BUDGET BUILD UP- INDIA'S TOP MINISTERS: AT 1 PM & 10:30 PM, SUN 3 PM
IF FUEL AND BANK LIABILITIES ARE NOT PAID ON TIME, THE OPS COULD STOP
TO EMPLOYEES: NEED TO UNDERSTAND THAT CO IS IN DIRE FINANCIAL STRAITS
FOREIGN FUNDS NET BUY RS.210.82 CR IN EQUITIES ON JULY 3 (PROVISIONAL)
DOMESTIC FUNDS NET BUY RS.298.58 CR IN EQUITIES ON JULY 3 (PROVISIONAL)
RIL YET TO CHALLENGE BOMBAY HC ORDER WHICH WAS IN FAVOUR OF RNRL IN SC
RIL FILES A CAVEAT IN SC IN RESPONSE TO RNRL'S SPECIAL LEAVE PETITION
CLB ORDER IN THE MATTER OF MAHINDRA SATYAM EXPECTED ON MONDAY
RIL FILES A CAVEAT IN SC IN RESPONSE TO RNRL'S SPECIAL LEAVE PETITION
CLB ORDER ON THE MATTER EXPECTED ON MONDAY: SOURCES
OPEN TO 1-2 GOVT NOMINEES TO BE RETAINED FOR INVESTIGATION PURPOSE

Updated: 18/03/2008 | 08:54 PM IST

Top Stories

Rumi Dutta

Tuesday, March 18, 2008 (Mumbai)

Blog

Comments:

Read (0)

Post

Rate the story

As the world's largest drug maker Pfizer braces for big losses of billions of dollars with its blockbuster cholesterol drug lipitor facing generic competition, the company is now turning to India and China for respite.

For the fist time, Pfizer's Asia revenues were higher than its US sales.

"We have launched an Asia strategy on how to best partner with Asian countries and companies. With a two fold strategy we will ensure that we take advantage of advanced infrastructure in this region for drug development,” said Jorge Puente, VP – Medical & Regulatory Affairs, Asia, Pfizer Inc.

So far Pfizer's key focus in Asia was Japan but now Pfizer plans to focus its research initiatives on disease areas common in Asia. The company’s new oncology center in California is scouting for Indian partners to jointly develop drugs for cancers common in Asia.

The company says its clinical trial programmes are expected to substantially increase in India besides its research and development investment in the country.

Clearly, as the giant reorganises its global portfolio of research programmes in order to reallocate resources it looks like India is well positioned to play a critical role in the next growth phase of this $50 billion giant.